Progressive Corporation
No price chart data available for 1D timeframe.
Rating
Why Price Moved
Shares are trading higher after the stock was upgr...
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
The Progressive Corporation, an insurance holding company, offers a comprehensive range of insurance products and associated services across the United States. Its portfolio includes personal and comm...
Latest News
6 days ago · globenewswire.com
Progressive Announces Investor Relations CallMAYFIELD VILLAGE, OHIO, Oct. 27, 2026 (GLOBE NEWSWIRE) -- As previously announced, The Progressive Corporation (NYSE: PGR) will host an Investor Relations conference call on Tuesday, November 3, 2026, beginning at 9:30 a.m. eastern time. This quarterly call, which will consist of both a conference call and audio-only webcast, is scheduled to last 60 minutes and will consist of a question-and-answer session with Tricia Griffith, our CEO, and Andrew Quigg, our CFO. Call-in participants will be able to ask questions via phone, however, webcast participants will not be able to submit questions online.
10 days ago · businesswire.com
TG Therapeutics Announces Phase 1 Data Evaluating Azer-cel in Progressive Multiple Sclerosis in a Late-Breaking Oral Presentation at MSToronto2026NEW YORK--(BUSINESS WIRE)---- $TGTX--TG Therapeutics, Inc. (NASDAQ: TGTX), today announced initial results from the Company's Phase 1 study evaluating azercabtagene zapreleucel (azer-cel), an investigational, allogeneic CD19-directed chimeric antigen receptor (CAR) T-cell therapy, in patients with progressive multiple sclerosis (MS). The data represent the first reported clinical evaluation of an allogeneic CD19-directed CAR T-cell therapy in progressive MS and were presented in a late-breaking oral sess.
10 days ago · businesswire.com
Bristol Myers Squibb Presents Results from Phase 1 Breakfree-2 Study of Zolacabtagene Autoleucel (BMS-986353) in Patients with Highly Active Relapsing and Progressive Forms of Multiple Sclerosis at MSToronto 2026PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CARTCellTherapy--Bristol Myers Squibb Presents Results from Phase 1 Breakfree-2 Study of Zolacabtagene Autoleucel (BMS-986353) in Patients.
10 days ago · globenewswire.com
Kyverna Therapeutics Highlights Promising Updated Clinical Data with Miv-cel in Progressive Multiple Sclerosis at MS Toronto 2026Single-dose miv-cel continues to demonstrate promising clinical benefit in progressive multiple sclerosis, achieving robust CAR T-cell penetration in the central nervous system (CNS) and improving disability scores while removing the need for chronic immunotherapies
11 days ago · zacks.com
Progressive (PGR) Upgraded to Buy: Here's WhyProgressive (PGR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
12 days ago · zacks.com
Progressive's Rising Auto Premiums Support Growth and UnderwritingPGR's rising auto premiums, expanding policy base and improved underwriting profitability support growth as competition intensifies in the U.S. auto market.
12 days ago · zacks.com
Here is What to Know Beyond Why The Progressive Corporation (PGR) is a Trending StockProgressive (PGR) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
18 days ago · seekingalpha.com
Progressive: A Great Insurer, But Slowing Growth Justifies A 'Hold'The Progressive Corp. is rated a 'Hold,' reflecting strong underwriting and durable demand but tempered by slowing premium growth and uncertain earnings momentum. PGR's Q3 2026 combined ratio improved to 88.7%, yet net premiums written grew just 4% YoY, with September monthly growth slowing to 2%. Valuation appears fair at a trailing P/E of 10.7x, but a weaker forward EPS outlook could pressure the multiple and limit upside.
18 days ago · seekingalpha.com
The Progressive Q3 Panic Is OverdoneThe Progressive's Q3 was a disappointment, but it isn't a sell signal for me. I'm still holding my shares, and I am maintaining my buy rating. Premium growth came in at 1%, auto policies dropped 31,000 in a month, and the underlying loss ratio hit 68.7, the highest in two years. The combined ratio sits at 88.7, or 91.1 without reserve releases, well under the sub-96 target. Every segment is under 96.
19 days ago · zacks.com
Progressive's Q3 Earnings Top Estimates on Higher PremiumsProgressive's Q3 earnings beat estimates as higher premiums and an improved combined ratio boosted results, while September policy growth remained strong.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove PGR